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Abstract
The vasculoprotective properties of delphinidin are driven mainly by its action on endothe-
lial cells. Moreover, delphinidin displays anti-angiogenic properties in both in vitro and in
vivo angiogenesis models and thereby might prevent the development of tumors associ-
ated with excessive vascularization. This study was aimed to test the effect of delphinidin
on melanoma-induced tumor growth with emphasis on its molecular mechanism on endo-
thelial cells. Delphinidin treatment significantly decreased in vivo tumor growth induced by
B16-F10 melanoma cell xenograft in mice. In vitro, delphinidin was not able to inhibit
VEGFR2-mediated B16-F10 melanoma cell proliferation but it specifically reduced basal
and VEGFR2-mediated endothelial cell proliferation. The anti-proliferative effect of delphi-
nidin was reversed either by the MEK1/2 MAP kinase inhibitor, U-0126, or the PI3K inhibi-
tor, LY-294002. VEGF-induced proliferation was reduced either by U-0126 or LY-294002.
Under these conditions, delphinidin failed to decrease further endothelial cell proliferation.
Delphinidin prevented VEGF-induced phosphorylation of ERK1/2 and p38 MAPK and
decreased the expression of the transcription factors, CREB and ATF1. Finally, delphinidin
was more potent in inhibiting in vitro cyclic nucleotide phosphodiesterases (PDEs), PDE1
and PDE2, compared to PDE3-PDE5. Altogether delphinidin reduced tumor growth of mel-
anoma cell in vivo by acting specifically on endothelial cell proliferation. The mechanism
implies an association between inhibition of VEGF-induced proliferation via VEGFR2 sig-
nalling, MAPK, PI3K and at transcription level on CREB/ATF1 factors, and the inhibition of
PDE2. In conjunction with our previous studies, we demonstrate that delphinidin is a prom-
ising compound to prevent pathologies associated with generation of vascular network in
tumorigenesis.
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Introduction
Epidemiologic studies have shown that a diet rich in fruits and vegetables has a beneficial pre-
ventive effect for cardiovascular diseases and cancer [1–3]. We previously reported that the
anthocyanin delphinidin possesses the same pharmacological profile as a total extract of red
wine polyphenolic compounds to promote endothelial nitric oxide (NO) production via the
activation of oestrogen receptor alpha [4,5], the increase of intracellular calcium concentration
and activation of tyrosine kinases [6]. In addition, we have demonstrated that delphinidin
displays anti-angiogenic properties in both in vitro and in vivo angiogenesis models [7–10].
Delphinidin acts on different steps leading to neovascularization including migration and pro-
liferation induced by vascular endothelium growth factor (VEGF) in endothelial cells. The
mechanisms involved include activation of ERK1/2, cyclin dependent-pathway and inhibition
of VEGF-induced mitochondrial biogenesis [7–10] and inhibition of VEGF receptor 2
(VEGFR2) trans-activation [11]. Angiogenesis represents an essential step in tumor develop-
ment and metastasis [12]. Then, during the vascular stage, tumor nutrition through diffusion is
no longer sufficient and formation of new vasculature is necessary for tumor growth. Anti-
angiogenic agents are now considered as an important cancer therapy option.
Based on the anti-angiogenic property of delphindin, the purpose of the present study was
first, to investigate the effect of delphinidin on in vivo tumor growth induced by B16-F10 mela-
noma cell xenograft in mice, to characterize the respective contribution of melanoma and
endothelial cells in delphinidin effects and consequently to decipher how delphinidin interacts




Delphinidin (chloride form) was purchased from Extrasynthese (Genay, France) and Trans-
MIT (Marburg, Germany). Human serum (HS) was from PromoCell and DMEM was from
ATCC. All other cell culture products were from Lonza. Hybond-P polyvinylidene fluoride
(PVDF) membranes, enhanced chemiluminescence (ECL) assay kit, and autoradiography films
were from GE Healthcare. Horseradish peroxidase (HRP)-conjugated secondary antibodies
were from Promega. The ReblotTM plus kit from Chemicon was used for stripping membranes.
The primary antibodies for total and phosphorylated ERK1/2 were from Sigma: anti-MAP
Kinase-ERK1/2 (#M5670); anti-activated MAP Kinase-diphosphorylated (Thr183 and Tyr185 in
ERK-2) ERK1/2 (#M8159). The primary antibodies for total and phosphorylated p38 MAP
kinase were from Cell Signaling: anti-p38 MAPK (#9212); anti-phospho (Thr180/Tyr182); p38
MAPK (#9211). The primary antibodies for total and phosphorylated CREB were from Cell
Signaling: phospho-CREB (Ser133) antibody (#9191) and CREB antibody (#9192). The phos-
pho-CREB antibody was also used to detect the phosphorylated ATF1 (Ser63). All other
Western blotting reagents were from Sigma. U-0126 [1,4-diamino-2,3-dicyano-1,4-bis(2-ami-
nophenylthio)-butadiene] was used as MEK1/2 MAP kinase inhibitor [13] and was from Bio-
mol. LY-294002 [2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] was used as PI3
kinase inhibitor [14] and was from Euromedex. Recombinant human VEGF was from Cell
Concepts. The primary antibodies for total and phosphorylated VEGFR2 were from (Cell sig-
naling Technology). Ki8751, the specific inhibitor of VEGFR2 tyrosine kinase [15], was pur-
chased from Santa Cruz Biotechnology.
Delphinidin was used in ethanol for tumor experiments and in dimethylsulfoxide (DMSO)
for cell proliferation and protein expression experiments. U-0126 and LY-294002 were
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prepared in DMSO. The final concentration of DMSO in experiments never exceeded 0.1%.
Control groups received the vehicle alone.
Cells and animals
B16-F10 (ATCC1 CRL-6475 ™, C57BL/6J strain, batch # 3225557) mouse melanoma cells
were purchased on March 2005 from American Type Culture Collection (LGC, Promochem,
Molsheim, France). Primary human umbilical vein endothelial cells (HUVECs) were prepared
as previously described [16], by collagenase digestion of freshly delivered umbilical cords
obtained after written consent obtained by the “Service de Maternité” in the “Centre Hospi-
talo-Universitaire de Hautepierre de Strasbourg” (www.chru-strasbourg.fr/poles/Gynecologie-
obstetrique) according to the principles expressed in the Declaration of Helsinki.
C57BL/6N mice (6 week old male, 20 g of weight) were obtained from Charles River. Mice
were maintained in controlled temperature room (25°C) with a 12 hour-light/dark cycle and
were provided with food and water ad libitum. This investigation was carried out in accordance
with the Guide for the Care and Use of Laboratory Animals (National Institutes of Health Pub-
lication no. 85–23, revised 1996) and received authorization from the “Comité Régional d'Ethi-
que en Matière d'Expérimentation Animale de Strasbourg” President: Fabielle Angel-Urban,
Institut de Physiologie Faculté de Médecine, Université Louis Pasteur, 11 rue Humann 67085
Strasbourg (CEEA 35, approved by the Ministère de l’Enseignement Supérieur et de la Recherche
(CREMEAS, number: AL/02/06/05/09) http://www-ulp.u-strasbg.fr/cremeas/. The ethics com-
mittee of the University of Strasbourg specifically approved this study as well as the consent
procedure.
Mouse xenografts and treatments
Two groups of 7 male C57BL/6N mice were used at 6 weeks old for tumor induction. The
experimental protocol is illustrated on in Fig 1A. Before any treatments, mouse weights were
registered on day 1 (D1). On the following day (D2), all mice were subcutaneously injected on
the ventral side near each hindleg with B16-F10 melanoma cells (25x104 cells in 100 μl of 0.9%
NaCl). The seventh day after tumor cell inoculation (D9), mice were treated by i.p. injection
(100 μl/10 g mice) with either drug solvent (1% ethanol) or 10 mg delphinidin/kg. Delphinidin
as well as solvent injections were repeated twice at 7-day intervals (D16 and D23). Then, seven
days later (D30) after pentobarbital anesthesia, mice were sacrificed by cervical dislocation and
tumors were dissected and weighted. Mouse weights were registered over 30 days on D1, D5,
D8, D12, D15, D20, D23, D26 and D30.
Cell culture
B16-F10 cell line and HUVECs were cultured at 37°C in a humidified incubator (5% CO2).
The cell line B16-F10 was cultured in T-175 flasks in DMEM supplemented with 100 U/ ml
penicillin, 100 μg/ ml streptomycin and 10% heat-inactivated foetal calf serum. Cells were har-
vested by trypsination, washed with 0.9% NaCl and resuspended to get a density of 25x104 cells
in 100 μl of 0.9% NaCl and used right away for the tumor growth experiments.
HUVECs were grown on plastic flasks coated with 60 mg/l type I collagen and cultured in
M199/RPMI 1640 (50:50, v/v) containing 2 μmol/ml ultraglutamine I, 100 U/ ml penicillin,
100 μg/ ml streptomycin, 2.5 μg/ml fungizone and supplemented with 20% serum, i.e. 10% of
human serum (HS) + 10% of heat-inactivated foetal calf serum (high serum culture medium)
as described previously [16]. Cells were used at the second passage.
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Fig 1. Effect of delphinidin onmouse tumor development.Mouse xenografts and treatments were
conducted as described in Materials and Methods. (A) Experimental protocol and delphinidin effect on mouse
weight. Mice were receiving delphinidin (●) or the vehicle of delphinidin as control (). (B) Effect of delphinidin
on tumor weight. On the 30th day, mice were sacrificed and tumors were dissected. In comparison with
control: * (P < 0.05).
doi:10.1371/journal.pone.0145291.g001
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Melanoma cell proliferation
B16-F10 (5,000 cells per well) were seeded on 96-multiwell plates in completed medium and
allowed to attach overnight. The medium was then replaced and cells were treated with or
without 10 ng/ml of VEGF, in presence or in absence of 10 μg/ml delphinidin. Proliferation
was determined at 24 h, 48 h and 72 h by a fluorimetric assay using the CyQUANT Cell Prolif-
eration Assay Kit (Molecular Probes, Eugene, OR). After growth medium removal, dye-bind-
ing solution was added into each microplate well and cells were incubated at 37°C for 45
minutes. The fluorescence levels were read on a fluorescent microplate reader (Synergy HT,
Biotek, Winooski, VT) with filters for 485 nm excitation and 530 nm emission [17].
Endothelial cell proliferation
HUVECs (12,000 cells per well) were seeded on 24-multiwell plates, or in the case of VEGFR2
studies HUVECs (10000 cells per well) were seeded on 96-multiwell plates, in high serum cul-
ture medium and allowed to attach for 4–5 h. The 20% serum medium was then replaced by
1% HS medium. After 24 h incubation, medium was removed and replaced with 500 μl /well or
280 μl/well (for VEGFR2 studies) of 1% HS medium containing tested substances. Cells were
pre-treated with or without a MEK1/2 MAP kinase inhibitor (U-0126, 10 μM) or a PI3 kinase
inhibitor (LY-294002, 10 μM), then treated with or without 10 ng/ml of VEGF, in presence or
in absence of 10 μg/ml delphinidin. Cells were allowed to proliferate for 3 days and HUVEC
proliferation was determined at 24 h, 48 h, and 72 h by a colorimetric assay using the ‘CellTiter
96 AQeous One Solution Cell Proliferation Assay’ from Promega [18].
Cells were pre-treated with or without a VEGFR2 specific inhibitor (Ki8751, 10 nM), then
treated with or without 10 ng /ml in presence or absence of 10 μg/ml delphinidin. Cells were
allowed to proliferate for 2 days and HUVECs proliferation was determined at 24 h and 48 h
by a colorimetric assay using the ‘CellTiter 96 AQeous One Solution Cell proliferation Assay’
from Promega.
VEGFR2 expression
HUVECs and B16-F10 cells were treated with delphinidin (10 μg/ml) for 3 h and then incu-
bated without or with VEGF (10 ng/ml) for 30 min for VEGFR2 phosphorylation or 24 h for
VEGFR2 expression. Then, the cells were homogenized, washed twice with PBS and trypsi-
nized. The cells were lysed with RIPA buffer freshly in presence of protease inhibitor. Cells
were allowed to lyse for 45 min on ice and centrifuged at 15000 g for 15 min at 4°C. The super-
natant was removed, and protein concentrations in the supernatant were determined by pro-
tein assay.
The proteins (30 μg) were separated on 10% sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) and transferred on the nitrocellulose membranes. The mem-
branes were incubated with anti-VEGFR2 or anti-pVEGFR2. The anti-β-actin (Sigma-
Aldrich) was used to visualize protein gel loading. The membranes were then incubated with
appropriate HRP-conjugated secondary antibody. The protein-antibody complexes were
detected by chemiluminescence using the Western Blotting Luminol reagent kit (Santa Cruz
Biotechnology1).
Signalling protein expression
HUVECs (9,000 cells per dish of 3.5 cm diameter) were seeded on petri dishes in high serum
culture medium and allowed to attach for 4–5 h. The 20% serum medium was then replaced by
1% HS medium. After 24 h incubation, medium was removed and replaced with 1 ml/petri
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dish of 1% HS medium with or without 10 ng/ml of VEGF, in presence or in absence of 10 μg/
ml delphinidin. After 30 min of treatment, cells were harvested directly in Laemmli sample
buffer (50 mM Tris-HCl, 0.005% bromophenol blue, 5% glycerol, 1% SDS, 2.5% β-mercap-
toethanol). Appropriate quantities of extracted proteins were resolved in a SDS-10% polyacryl-
amide gel and electro transferred onto PVDF membranes, as described previously [19].
Membranes were processed for immunoblotting with primary antibodies directed against
phosphorylated ERK1/2 (1/10,000), phosphorylated p38 MAP kinase (1/1,000), phosphory-
lated CREB (1/1,000), and phosphorylated ATF1 (1/1,000). Immobilized antigens were
detected by chemiluminescence using HRP-conjugates as secondary antibodies (1/60,000), an
ECL assay kit and autoradiography films. Autoradiography signals were captured on a Gene-
Genius Bio Imaging System (Syngene) using the GeneSnap software and analyzed using the
GeneTools software. After being stripped, membranes were re-probing with an antibody
directed against either total ERK1/2 (1/10,000) or total p38 MAP kinase (1/1,000) or total
CREB (1/1,000). Immobilized antigens were detected as described above.
Assessment of delphinidin effect on purified PDEs
PDE1, PDE3, PDE4 and PDE5 were isolated by anion-exchange chromatography from bovine
aortic smooth muscle cytosolic fraction as previously described [20]. PDE2 was isolated from
human platelets [21]. Purified PDEs were stored as aliquots at -80°C until use. PDE activity
was determined by a radio-enzymatic assay as described previously [20,22]. The concentration
of delphinidin that produced 50% inhibition (IC50) of substrate hydrolysis (determined at
1μM cAMP or cGMP) was calculated by non-linear regression analysis (GraphPad Prism, San
Diego, CA) of concentration-response curves performed with 1–300 μM of delphinidin and
included 6 different concentrations of delphinidin.
Statistical analysis
Results are expressed as mean ± SEM of n experiments. Student’s t test for unpaired data was
used for statistical analysis, with P< 0.05 being considered significant.
Results
Tumor development
The effect of delphinidin on mouse tumor development is illustrated on Fig 1. The evolution
over the 30 day experimentation of mouse weight as a percent of the starting weight of each
mouse (Fig 1A) was unchanged by delphinidin treatment (10 mg/kg i.p. once a week for 3
weeks) in comparison with non-treated mice (P = 0.914). Interestingly, delphinidin markedly
decreased significantly the tumor weight on the 30th day of experimentation by 83% (P = 0.02),
as shown on Fig 1B.
The cellular origin of the effect of delphinidin was further characterized both on melanoma
and endothelial cell proliferation.
Melanoma cell and endothelial cell proliferations
As illustrated on Fig 2 (Fig 2A), neither delphinidin (10 μg/ml), nor VEGF (10 ng/ml) alone or
in combination with delphinidin, were able to increase B16-F10 melanoma cell proliferation at
any time tested (i.e. 24, 48 and 72 h).
In HUVECs, delphinidin (10 μg/ml) significantly decreased the rate of basal proliferation
(-52% at 24 h, -66% at 48 h and -70% at 72 h, P< 0.0001 for each time point) (Fig 2B). As
expected, VEGF (10 ng/ml) significantly increased the proliferation rate (+ 50% at 24 h, + 186%
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Fig 2. Effect of delphinidin and VEGF onmelanoma cell (Fig 2A) and HUVEC proliferation (Fig 2B). (A)
B16-F10 melanoma cells were incubated for 24, 48 and 72 h in cell culture medium containing 1% human
serum with different additions. NT: non treated cells. DMSO: in presence of the solvent DMSO. and in
presence of 10 μg/ml delphinidin, 10 ng/ml VEGF or 10 μg/ml delphinidin + 10 ng/ml VEGF. Cell number is
expressed in arbitrary units. In each group n = 5. (B) HUVECs were incubated for 24, 48 and 72 h in cell
culture medium containing 1% human serum, in absence of any additions (Control) and in presence of 10 μg/
Delphinidin Effects on B16F10 Tumor Growth and Endothelial Signalling
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at 48 h and + 337% at 72 h, P< 0.0001 for each time-point). Interestingly, delphinidin
completely prevented the ability of VEGF to induce endothelial cell proliferation at any time-
point tested (-56% at 24 h, -85% at 48 h and -130% at 72 h; P< 0.0001 for each time point) and
restored to some extent a proliferation rate close to the basal proliferation.
Melanoma cell and endothelial VEGFR2-mediated cell proliferations
As expected, HUVECs express VEGFR2 (Fig 3) and VEGF increased both VEGFR2 expression
(Fig 3A) and phosphorylation (Fig 3C). Interestingly, delphinidin alone had no effect but it
completely prevented the ability of VEGF in increasing both VEGFR2 expression and phos-
phorylation. Moreover, the ability of VEGF to increase endothelial cell proliferation was
completely abolished in the presence of the VEGFR2 specific inhibitor, Ki8751 (Fig 3E). Inter-
estingly, delphinidin inhibited VEGF-induced proliferation and in this respect Ki8751 did not
inhibit further this response. Altogether, these results demonstrate that delphinidin inhibits
VEGF induced proliferation via the inhibition of VEGFR2 activation and expression.
In contrast to HUVECs, B16-F10 melanoma cells, although VEGF increased VEGFR2 phos-
phorylation after 30 min stimulation (Fig 3B), it did not modify VEGFR2 expression (Fig 3D).
Since, VEGF was not able increase B16-F10 melanoma cells proliferation (Fig 2A), one can
advanced the hypothesis that the ability of VEGF to enhance VEGFR2 phosphorylation was
not sufficient on its own to activate all signalling pathways leading to proliferation. Taken
together, these data reinforce our conclusion that the effect of delphinidin on melanoma-
induced tumor growth in both in vivo and in vitro is mainly due to its action on endothelial
cells. Therefore, the present study was focused on delphinidin participation in endothelial cell
signalling.
Proliferation and MEK-ERK-signalling pathway in endothelial cells
Fig 4 shows the effect of U-0126 (10 μM) on basal (Fig 4A) and VEGF-stimulated proliferation
in HUVECs (Fig 4B).
U-0126 (10 μM) slightly modified proliferation, although remaining near the basal level
(+ 19% at 24 h, P = 0.009; + 19% at 48 h, ns; - 30% at 72 h, P = 0.02). However, per se delphini-
din strongly inhibited basal rate proliferation. U-0126 reversed to some extent closer to basal
level the inhibitory effect of delphinidin (Fig 4A).
U-0126 prevented to some extent the VEGF-induced proliferation (- 13% at 24 h, ns; - 52%
at 48 h, P = 0.0004; - 70% at 72 h, P = 0.0022). Thus, the proliferation rate at 72 h was not sig-
nificantly different from the control proliferation rate (131% at 72 h, n.s.). Interestingly, no fur-
ther inhibition was observed when delphinidin was associated to U-0126, indicating that
maximal inhibitory effect was already reached with delphinidin alone (Fig 4B).
Proliferation and PI3 kinase-signalling pathway in endothelial cells
Fig 5 shows the effect of LY-294002 (10 μM) on basal (Fig 5A) and VEGF-stimulated prolifera-
tion (Fig 5B).
ml delphinidin, 10 ng/ml VEGF or 10 μg/ml delphinidin + 10 ng/ml VEGF. Cell proliferation rate is expressed in
% of control (n = 12). In comparison with control: ** (P < 0.01), **** (P < 0.0001). In comparison with the
respective incubation times—[Delphinidin+VEGF] versus Delphinidin: ¤ (P < 0.05)—[Delphinidin+VEGF]
versus VEGF: #### (P < 0.0001).
doi:10.1371/journal.pone.0145291.g002
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Fig 3. Effect of delphinidin and VEGF on VEGFR2. VEGFR2 Phosphorylation: (A) HUVECs and (B)
B16-F10 were treated with delphinidin (10 μg/ml) for 3 h and then incubated without or with VEGF (10 ng/ml)
for 30 min. HUVEC was cultured in M199/RPMI 1640 (50:50, v/v) containing 2 μmol/ml ultraglutamine I, 100
U/ ml penicillin, 100 μg/ ml streptomycin, 2.5 μg/ml fungizone and supplemented with 20% serum, i.e. 10% of
human serum (HS) + 10% of heat-inactivated foetal calf serum (high serum culture medium) as described
previously [16]. B16-F10 was cultured in DMEM supplemented with 100 U/ ml penicillin, 100 μg/ ml
Delphinidin Effects on B16F10 Tumor Growth and Endothelial Signalling
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LY-294002 significantly increased the basal proliferation at 24 h (+ 55%, P< 0.0001) and 48
h (+ 28%, P = 0.0068), but not at 72 h (Fig 5A). LY-294002 completely blunted the inhibitory
effect of delphinidin.
LY-294002 abolished the ability of VEGF to increase proliferation at any time tested (- 44%
at 24 h, P = 0.02; - 58% at 48 h, P = 0.03; - 83% at 72 h, P = 0.0001) (Fig 5B) and this, in absence
or in presence of delphinidin.
ERK1/2 and p38 MAP kinase in endothelial cells
Fig 6 shows that VEGF increased ERK1/2 activation (Fig 6A; + 153%, P = 0.005) and p38 MAP
kinase activation (Fig 6B; + 113%, P = 0.002). Delphinidin decreased slightly but significantly
basal ERK1/2 activation (- 25%, P = 0.0449) and abolished the ability of VEGF to activate this
MAP kinase (- 77%, P = 0.0030) (Fig 6A).
Delphinidin did not affect basal p38 MAP kinase activation, but it completely prevented the
activation of this kinase by VEGF (- 47%, P = 0.0246) (Fig 6B).
CREB and ATF1 in endothelial cells
Fig 6 shows that delphinidin alone had no significant effect but it completely prevented the
increase of CREB phosphorylation (+484%, P = 0.02) induced by VEGF (Fig 6C). Delphinidin
abolished the phosphorylation of ATF1 in the control conditions (P< 0.0001) as well as after
stimulation by VEGF (P = 0.0043) (Fig 6D).
Effect on purified PDE activities
PDEs play a critical role in intracellular cAMP and cGMP signalling [23]. We have previously
shown that different PDE families participate specifically in cell proliferation and migration as
well as in VEGF-induced angiogenesis [24,25]. Also, the present study investigated the effect
and the specificity of delphinidin towards PDE1 to PDE5 activities [26]. As illustrated on
Table 1, delphinidin inhibited the activity of PDE1 to PDE5 in the range of 5 to 40 μg/ml con-
centrations, in agreement with its effect on cellular proliferation. Interestingly, delphinidin
preferentially inhibited at similar concentrations the hydrolysis of cGMP by CaM/Ca-activated
PDE1 (IC50 value of 5 μM) and the hydrolysis of cAMP by cGMP-activated PDE2 (IC50 value
of 6 μM).
Discussion
Angiogenesis is critical for tumor development, and neovascularization is now known as a pre-
requisite to the rapid expansion of tumor cells associated with formation of macroscopic
streptomycin and 10% heat-inactivated foetal calf serum. After treatment cells were harvested, cell lysates
were prepared and the VEGFR2 expression and phosphorylation were determined. (A) and (B) represent the
ratio of phosphorylated over total VEGFR2. Data are means ± SEM of n = 5 experiments. *P < 0.05 versus
DMSO, ** P < 0.01 versus VEGF, ** P < 0.01 versus VEGF. VEGFR2 expression. (C) HUVECs and (D)
B16-F10 were treated with delphinidin (10 μg/ml) for 3 h and then incubated without or with VEGF (10 ng/ml)
for 30 min for VEGFR2 phosphorylation or 24 h for VEGFR2 expression. (A) and (B) represent the ratio of
phosphorylated over total VEGFR2. Data are means ± SEM of n = 5 experiments. * P < 0.05 versus DMSO,
** P < 0.01 versus VEGF, ** P < 0.01 versus VEGF. Effect of delphinidin, VEGF and Ki8751 on HUVECs
proliferation (E). HUVECs were incubated for 24 and 48 h in cell culture medium containing 1% human
serum with different experimental conditions: Control, 10 ng/ml VEGF, 10 nM Ki8751 + 10 nM VEGF, 10 μg/
ml delphinidin + 10 nM VEGF, 10 nM Ki8751 + 10 μg/ml delphinidin + 10 nM VEGF. Cell proliferation rate is
expressed in % of control (n = 5). In comparison with control: *P < 0.05, ** P < 0.01. in comparison with the
respective incubation times -[Ki8751 + VEGF] versus VEGF: # P < 0.05, ## P < 0.01 –[delphinidin+ VEGF]
versus VEGF: § P < 0.05, §§ P < 0.01 –[Ki8751+delphinidin+VEGF] versus [Ki8751+VEGF]: ££ P < 0.01.
doi:10.1371/journal.pone.0145291.g003
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Fig 4. Effect of U-0126 and delphinidin on cellular proliferation. HUVECs were incubated for 24, 48 and
72 h in cell culture medium containing 1% human serum with different additions. (A) Basal proliferation: no
addition (Control), in presence of 10 μMU-0126, 10 μg/ml delphinidin, and 10 μMU-0126 + 10 μg/ml
delphinidin. (B) VEGF-stimulated proliferation: no addition (Control), 10 ng/ml VEGF, 10 μMU-0126 + 10 ng/
ml VEGF, 10 μg/ml delphinidin + 10 ng/ml VEGF, 10 μMU-0126 + 10 μg/ml delphinidin + 10 ng/ml VEGF.
Cell proliferation rate is expressed in % of control (n = 9). In comparison with control for (A) and (B): *
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tumors. Based on our previous data showing that delphinindin displays anti-angiogenic prop-
erties both in vitro and in vivo, its effect on tumor growth induced by B16-F10 melanoma cell
xenograft was investigated in mice. The results suggest that delphinidin markedly reduces the
increase of tumor growth in vivo by its action on endothelial but not on B16-F10 melanoma
cell proliferation. The mechanism implies an association between the inhibition of VEGF-
induced proliferation via MAPK and PI3K, the inhibition at transcription level on CREB/
ATF1 factors, and the inhibition of PDE2 in endothelial cells.
In vivo delphinidin treatment reduced tumor growth induced by B16-F10 melanoma cell
xenograft. It decreased tumor weight by 83% on the 30th day of experimentation. Interestingly,
no significant weight loss (%) was observed along the treatment indicating that delphinidin
treatment did not induce adverse effect leading to weight loss. Moreover, these data reinforce
the hypothesis that delphinidin acts specifically in reduced tumor growth weight. Interestingly,
these data are strengthened by very recent data obtained for tumor growth induced by non-
small-cell lung cancer cells in nude mice (NSCLC) [27]. Indeed, these authors have found that
in athymic nude mice subcutaneously implanted with human NSCLC cells, delphinidin treat-
ment causes: (i) a significant inhibition of tumor growth, (ii) a significant decrease in the
expression of markers for cell proliferation (Ki67 and PCNA) and angiogenesis (CD31 and
VEGF), and (iii) a significant induction of apoptosis, when compared with control mice.
To go any further in the molecular mechanism of delphinidin in the inhibition of tumor
growth, we investigated in vitro on one hand the effect of delphinidin on B16-F10 melanoma
cell proliferation linked to tumor induction and on the other hand on endothelial cell prolifera-
tion directly linked to angiogenesis.
Surprisingly, we found that delphinidin did not overcome basal- and VEGF-induced mela-
noma cell proliferation whereas interestingly delphinidin over 72 h of treatment significantly
and potently inhibited basal and VEGF-induced endothelial cell proliferation as previously
shown [8]. To go further, the expression and the phosphorylation of VEGFR2 receptor was
studied in both endothelial and melanoma cells. Furthermore the compound Ki8751, which
selectively antagonizes VEGFR2 receptor [28], was used for studying VEGF-induced cell prolif-
eration in endothelial cells. The data clearly show that both cells express VEGFR2 which
VEGF-dependent phosphorylation is inhibited by delphinidin treatment at the early stage of
stimulation (i.e. 30 min) at which no change in VEGFR2 expression was observed yet. In con-
trast, VEGFR2 expression was increased after 24 h of incubation. Under these experimental
conditions, delphinidin completely prevented the increase of VEGFR2 expression in HUVECs
but not in B16-F10 cells. Taken together, these data reinforce our conclusion that the effect of
delphinidin on melanoma-induced tumor growth in both in vivo and in vitro is mainly due to
its action on endothelial cells and probably VEGFR2 signalling participates to its action.
These results suggest that the main target of delphinidin in reducing several angiogenic fac-
tors, including tumor growth, is due to its action on endothelium-dependent angiogenesis,
although one cannot exclude that it might affect B16-F10 melanoma cell proliferation in vivo.
Indeed, one study shows that oral consumption of delphinidin delays tumor growth in a lung
carcinoma xenografted model through an inhibition of PDGF ligand/receptor signalling. This
inhibitory effect of delphinidin on PDGF-R leads to the inhibition of PDGF-induced activation
of ERK-1/2 signalling [29].
(P < 0.05); ** (P < 0.01); *** (P < 0.001); **** (P < 0.0001). In comparison with the respective incubation
times—[U-0126+Delphinidin] versus Delphinidin: ¤ (P < 0.05); ¤¤¤ (P < 0.001)—[U-0126+VEGF] versus
VEGF: §§ (P < 0.01); §§§ (P < 0.001)—[Delphinidin+VEGF] versus VEGF: ## (P < 0.01); ### (0.001); ####
(P < 0.001)—[U-0126+Delphinidin+VEGF] versus [U-0126+VEGF]: †† (P < 0.01).
doi:10.1371/journal.pone.0145291.g004
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Fig 5. Effect of LY-294002 and delphinidin on cellular proliferation. HUVECs were incubated for 24, 48
and 72 h in cell culture medium containing 1% human serum with different additions. (A) Basal proliferation:
no addition (Control), in presence of 10 μM LY-294002, 10 μg/ml delphinidin, and 10 μM LY-294002 + 10 μg/
ml delphinidin. (B) VEGF-stimulated proliferation: no addition (Control), 10 ng/ml VEGF, 10 μM LY-294002
+ 10 ng/ml VEGF, 10 μg/ml delphinidin + 10 ng/ml VEGF, 10 μM LY-294002 + 10 μg/ml delphinidin + 10 ng/
ml VEGF. Cell proliferation rate is expressed in % of control (n = 3). In comparison with control for (A) and (B):
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VEGF significantly increased HUVEC proliferation up to 72 h. The time-dependent study
showed that this increase was already significant at 24 h in agreement with its 24 h-effect on
cell cycle progression [8] and increased with time. Delphinidin treatment per se decreased
significantly and potently basal and VEGF-induced proliferation rate (stabilized at 72 h
* (P<0.05); ** (P<0.01); *** (P<0.001); **** (P<0.0001). In comparison with the respective incubation
times–[LY-294002+VEGF] versus VEGF: § (P < 0.05)–[LY-294002+Delphinidin+VEGF] versus [LY-294002
+VEGF]: † (P < 0.05).
doi:10.1371/journal.pone.0145291.g005
Fig 6. Effect of delphinidin and VEGF on ERK1/2 (Fig 6A), p38 MAP kinase activation (Fig 6B), CREB (Fig 6C) and ATF1 (Fig 6D) transcription factor
activation.HUVECs were treated for 30 minutes with or without 10 μg/ml delphinidin, in absence or presence of 10 ng/ml VEGF. Analysis of 30 μg protein
was performed in each condition. (A) Densitometry represents the ratio of phosphorylated (a) over total (b) ERK1/2 and is expressed in % of control (n = 4). In
comparison with control: * (P < 0.05), ** (P < 0.01), *** (P < 0.001). In comparison with VEGF: ## (P < 0.01). (B) Densitometry represents the ratio of
phosphorylated (a) over total (b) p38 and is expressed in % of control (n = 4). In comparison with control: ** (P < 0.01). In comparison with VEGF: #
(P < 0.05). (C) Densitometry represents the ratio of phosphorylated (a) over total (b) CREB and is expressed in % of control (n = 4). In comparison with
control: * (P<0.05). In comparison with VEGF: # (P<0.05). (D) Densitometry represents the ratio of phosphorylated ATF1 (a) over total CREB (b) and is
expressed in % of control (n = 4). In comparison with control: **** (P < 0.0001). In comparison with VEGF: ## (P < 0.01).
doi:10.1371/journal.pone.0145291.g006
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treatment) suggesting that it acts on canonical pathways implicated in basal as well as VEGF-
activated intracellular signalling. VEGF via VEGF-R2 is the most important pathway in induc-
ing endothelial cell proliferation, migration and tube formation leading to angiogenesis. Thus,
delphinidin exerts its anti-angiogenic activity, at least in part, by inhibiting VEGF-R2 activa-
tion. VEGF signalling is mediated by activation of extracellular signal-regulated kinase ERK1/2
[30] and via Akt activation [31]. Furthermore, signalling by the PI3-AKT [32] and MEK1/
2-ERK1/2 pathways can collaborate to maintain cell viability [33].
In the present study, delphinidin reduced basal proliferation by a mechanism sensitive both
to ERK1/2 inhibitor in association with diminished ERK1/2 phosphorylation and to PI3K/Akt
inhibitor. In conjunction with these results, we have previously reported that delphinidin in
basal condition displays anti-proliferative effect through an ERK1/2 phosphorylation, indepen-
dent of nitric oxide pathway and this effect is correlated with suppression of cell progression by
blocking the cell cycle in G0/G1 phase in bovine aortic endothelial cells [8]. According to a
mouse Matrigel plug assay, the anti-angiogenic properties of delphinidin is mediated via an
inhibition of vessel formation by basic FGF-2 and PDGF [29]. Serum used in the present study
contains several growth factors including PDGF. Thus, one can advance the hypothesis that
the inhibitory effect of delphinidin on basal proliferation might be due to its effect on PDGF
signalling. Altogether, delphinidin affects basal endothelial proliferation by acting on ERK1/2
and PI3K/Akt.
The most important findings of the present study were that delphinidin was able to prevent
VEGF-induced proliferation and activation of both ERK 1/2 and p38 MAP kinase by a mecha-
nism sensitive to PI3/Akt inhibitors. These data strengthened our previous studies showing
that delphinidin in vitro prevents VEGF-induced increase of mitochondrial biogenesis and
activation of Akt pathway [10] and delphinidin in vivo reduces angiogenesis similarly to that
obtained with high dose of red wine polyphenols via an inhibition of NO/VEGF and Akt/PI3K
pathways [9]. In the later study, MMP activity is also reduced by delphinidin in association
with p38 MAP kinase and NF-kappaB expression. Altogether, these data are consistent with
the fact that delphinidin might inhibit phosphorylation of VEGF-R2 and consequently dimin-
ish multiple signalling pathways activated by VEGF in endothelial cells in a similar fashion
than that reported by Lamy et al. 2006 [34].
Since inhibitor of p38 MAPK signalling is able to block the CREB phosphorylation in
HUVEC [35], it was of interest to investigate the effect of delphinidin on the phosphorylation
of CREB and ATF1 transcription factor [36] which are regulated by MAPK and PI3K signalling
and participates to cAMP signalling. The present study underscores for the first time that del-
phinidin was able to overcome the VEGF-induced phosphorylation of both transcription fac-
tors, this effect being maximal on ATF1 phosphorylation. These phosphorylations are a
requisite for their DNA binding [36]. Interestingly, in absence of VEGF delphinidin already
Table 1. IC50 values of delphinidin on purified PDE1 to PDE5 (μg/ml, μM).
PDE1 PDE2 PDE3 PDE4 PDE5
Substrate cGMP cGMP cAMP cAMP cAMP cAMP cGMP
Regulator +CaM/Ca +5μM cGMP
μg/ml 11±2 5±1 35±3 6±1 12±2 37±4 15±2
μM 33±6 15±3 103±9 18±3 35±6 109±12 44±6
These data were preliminarily reported [26] and represented the mean of 3 determinations ± S.E.M.
doi:10.1371/journal.pone.0145291.t001
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inhibited ATF1 phosphorylation. This mechanism might explain and contribute to the delphi-
nidin anti-proliferative effect on basal proliferation.
Finally, our previous studies have clearly demonstrated that among the cyclic nucleotide
phosphodiesterase families (PDE1-PDE11; for review see [23] and [25]), PDE2 and PDE4 spe-
cifically control intracellular cAMP second messenger in HUVECs and participate to the con-
trol of VEGF-induced angiogenesis [16,24,37]. Notably, they control HUVEC migration,
proliferation and cell cycle progression by modulating the expression of protein partners of
VEGF signalling cascade, such as MAP kinase, cyclin A, cyclin D1, p21 and p27 [24,38]. Addi-
tively, we showed that polyphenols are able to differently inhibit PDE1 to PDE5 and to control
vascular function [39,40]. In the present study delphinidin inhibited selectively the hydrolysis
of cGMP by Ca++/CaM activated PDE1 and the hydrolysis of cAMP by cGMP-activated PDE2
in a concentration range that is in agreement with its effectiveness on tumor growth and in
vitroHUVEC proliferation. Although delphinidin (10 μg/ml) did not inhibit in vitro B16-F10
proliferation, it might nevertheless partially explain the decrease of B16F10 tumor growth
induced by delphinidin in vivo, since PDE1 inhibition per se reduces B16F10 melanoma cell
proliferation [41]. Additively, delphinidin similarly to PDE2 inhibitor decreased VEGF-
induced HUVEC proliferation [16]. Concerning the PDE2 contribution in VEGF induced
HUVEC proliferation, it is of interest to know that: i) PDE2 might be activated by PMA-stimu-
lated PKC [42]; ii) PDE2 is overexpressed in VEGF-stimulated HUVEC and its selective inhibi-
tion overcome HUVEC proliferation and migration [16,24,43]; iii) PMA markedly increased
the expression of VEGF in HUVEC indicating that PKC is a key partner of VEGF signalling
cascade [44]. Therefore, delphinidin might be helpful for the prevention and treatment of can-
cer, possibly by acting on PDE1 and PDE2, which regulate cyclic nucleotide levels.
In summary, delphinidin reduced tumor growth of melanoma cell in vivo by acting specifi-
cally on endothelial cell proliferation assessed by its selective effect towards endothelial cell
VEGFR2 signalling. The mechanism implies an association between: (i) the inhibition of
VEGF-induced proliferation via MAPK and PI3K; (ii) the inhibition at transcription level of
the VEGF-induced phosphorylation of CREB/ATF1 factors; and (iii) the inhibition of PDE2.
In conjunction with our previous study, we demonstrate that delphinidin is a promising com-
pound to prevent pathologies associated with generation of vascular network in tumorigenesis.
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